226950 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
OliX Pharmaceuticals, Inc. engages in the research and development of treatments and the manufacture and sale of new drugs. It develops acid-based therapeutics based on ribonucleic acid interference (RNAi) technology. It offers hypertrophic scar treatments, subretinal fibrosis treatments, rod-cone dystrophy treatments, age-related macular degeneration products, and others. The company was founded by Dong-Ki Lee on February 26, 2010 and is headquartered in Suwon-si, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
226950 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company